ELVN Valuation

Enliven Therapeutics Inc

Add to Watchlist

Advanced Chart

17.630

-0.67(-3.661%)1D

ELVN Relative Valuation

ELVN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ELVN is overvalued; if below, it's undervalued.

Historical Valuation

Enliven Therapeutics Inc (ELVN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 17.63 is considered Undervalued compared with the five-year average of -9.14. The fair price of Enliven Therapeutics Inc (ELVN) is between 14375.38 to 134623.38 according to relative valuation methord. Compared to the current price of 17.63 USD , Enliven Therapeutics Inc is Undervalued By 99.88%.

Relative Value

Fair Zone

14375.38-134623.38

Current Price：17.63

99.88%

Undervalued

-9.07

Trailing

Forward

-3.93

EV/EBITDA

Enliven Therapeutics Inc. (ELVN) has a current EV/EBITDA of -3.93. The 5-year average EV/EBITDA is -4.63. The thresholds are as follows: Strongly Undervalued below -9.58, Undervalued between -9.58 and -7.10, Fairly Valued between -2.15 and -7.10, Overvalued between -2.15 and 0.32, and Strongly Overvalued above 0.32. The current Forward EV/EBITDA of -3.93 falls within the Historic Trend Line -Fairly Valued range.

-4.24

EV/EBIT

Enliven Therapeutics Inc. (ELVN) has a current EV/EBIT of -4.24. The 5-year average EV/EBIT is -5.79. The thresholds are as follows: Strongly Undervalued below -10.68, Undervalued between -10.68 and -8.24, Fairly Valued between -3.35 and -8.24, Overvalued between -3.35 and -0.91, and Strongly Overvalued above -0.91. The current Forward EV/EBIT of -4.24 falls within the Historic Trend Line -Fairly Valued range.

17.63

Enliven Therapeutics Inc. (ELVN) has a current PS of 17.63. The 5-year average PS is 86151.25. The thresholds are as follows: Strongly Undervalued below -117828.55, Undervalued between -117828.55 and -15838.65, Fairly Valued between 188141.15 and -15838.65, Overvalued between 188141.15 and 290131.05, and Strongly Overvalued above 290131.05. The current Forward PS of 17.63 falls within the Historic Trend Line -Fairly Valued range.

-11.11

P/OCF

Enliven Therapeutics Inc. (ELVN) has a current P/OCF of -11.11. The 5-year average P/OCF is -10.56. The thresholds are as follows: Strongly Undervalued below -18.79, Undervalued between -18.79 and -14.67, Fairly Valued between -6.44 and -14.67, Overvalued between -6.44 and -2.32, and Strongly Overvalued above -2.32. The current Forward P/OCF of -11.11 falls within the Historic Trend Line -Fairly Valued range.

-10.94

P/FCF

Enliven Therapeutics Inc. (ELVN) has a current P/FCF of -10.94. The 5-year average P/FCF is -4.45. The thresholds are as follows: Strongly Undervalued below -16.77, Undervalued between -16.77 and -10.61, Fairly Valued between 1.71 and -10.61, Overvalued between 1.71 and 7.87, and Strongly Overvalued above 7.87. The current Forward P/FCF of -10.94 falls within the Undervalued range.

Enliven Therapeutics Inc (ELVN) has a current Price-to-Book (P/B) ratio of 2.14. Compared to its 3-year average P/B ratio of 2.70 , the current P/B ratio is approximately -20.90% higher. Relative to its 5-year average P/B ratio of 2.70, the current P/B ratio is about -20.90% higher. Enliven Therapeutics Inc (ELVN) has a Forward Free Cash Flow (FCF) yield of approximately -6.78%. Compared to its 3-year average FCF yield of -7.07%, the current FCF yield is approximately -4.19% lower. Relative to its 5-year average FCF yield of -7.07% , the current FCF yield is about -4.19% lower.

2.14

P/B

Median3y

2.70

Median5y

2.70

-6.78

FCF Yield

Median3y

-7.07

Median5y

-7.07

Competitors Valuation Multiple

The average P/S ratio for ELVN's competitors is 18.18, providing a benchmark for relative valuation. Enliven Therapeutics Inc Corp (ELVN) exhibits a P/S ratio of 17.63, which is -3.02% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ELVN.O

Enliven Therapeutics Inc

Dianthus Therapeutics Inc

Intellia Therapeutics Inc

9.52

51.27%

1.10B

Performance Decomposition

Market capitalization of ELVN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ELVN in the past 1 year is driven by Unknown.